In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma Source: Eur Respir J 2003; 21: 567-573 Year: 2003
Imaging the inflammatory activity of sarcoidosis Source: Eur Respir J 2013; 41: 743-751 Year: 2013
Visualization and quantification of muscarinic receptors by positron emission tomography (PET) in human lung in vivo Source: Eur Respir J 2001; 18: Suppl. 33, 227s Year: 2001
Influence of acute smoking on pulmonary inflammatory cell activity measured by positron emission tomography (PET) in asymptomatic cigarette smokers Source: Annual Congress 2005 - New modalities and application in lung and airway imaging Year: 2005
(18)F-FDG positron emission tomography/computed tomography and pulmonary function in sarcoidosis Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013
Positron emission tomography (PET) using 18 F-fluorodeoxyglucose (18 FDG) can detect radiographically ”occult“ lung cancer (ROLC) in the central airways Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001
Measurement of airway inflammation in smokers by means of positron emission tomography Source: Annual Congress 2012 - Functional imaging of the lung parenchyma, tumours and circulation Year: 2012
18F-fluorodeoxyglucose (18FDG) PET pulmonary imaging in COPD Source: International Congress 2015 – CT, PET, MRI modalities: fusion of anatomical and functional variables for lung assessment Year: 2015
Does positron emission tomography (PET/CT) have a role to play in the management of patients presenting with pleural changes suggestive of malignancy Source: Annual Congress 2009 - Diagnosis and management of pleural effusions and mesothelioma: improving old techniques and new tools Year: 2009
Single photon emission computed tomography (SPECT) in the non-invasive diagnosis cardiac sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 356s Year: 2006
Quantitative 18 F-fluorodeoxyglucose positron emission tomography/computed tomography to assess pulmonary inflammation in COPD Source: ERJ Open Res, 7 (3) 00699-2020; 10.1183/23120541.00699-2020 Year: 2021
A comparison of fluorodeoxyglucose positron emission tomography (FDG-PET) and transthoracic needle biopsy (TNB) in the management of single pulmonary nodules (SPN) Source: Annual Congress 2004 - Pneumothorax, chest drains Year: 2004
The role of positron emission tomography with 18F-2-fluoro-2-deoxy-D-glucose in respiratory oncology Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-34-0, page=245 Year: 2004
Fluorine-18-fluorodeoxyglucose positron emission tomography (18F-FDGPET) may be useful in the management of sarcoidosis Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014
Imaging of malignant pleural mesothelioma with fluordeoxyglucose positron emission tomography (FDG-PET) Source: Eur Respir J 2001; 18: Suppl. 33, 396s Year: 2001
Positron emission tomography (PET) and computed tomography (CT) in the assessment of the mediastinum for patients with presumed or established lung cancer Source: Annual Congress 2008 - Lung cancer and other malignant diseases involving the lungs Year: 2008
18F-Fluorodeoxyglucose (18FDG) PET pulmonary imaging: Role in detecting vascular inflammation Source: International Congress 2015 – CT, PET, MRI modalities: fusion of anatomical and functional variables for lung assessment Year: 2015
18F-FDG (fluorodeoxyglucose) uptake in focal organizing pneumonia mimicking bronchial carcinoma Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013
Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the clinical diagnosis of lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 227s Year: 2001
Interstitial lung disease (ILD) in juvenile systemic sclerosis (JSS): correlation between high-resolution computed tomography (HRCT) and pulmonary function test (PFT) changes Source: Annual Congress 2008 - Miscellaneous respiratory infections Year: 2008